Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Non-Current Deffered Revenue of $5.8 million for Q4 2025, up 202.41% year-over-year from $1.9 million in Q4 2024, and down 4.91% quarter-over-quarter from $6.1 million in Q3 2025.
Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 202.41% year-over-year to $5.8 million; the TTM figure through Dec 2025 stood at $5.8 million (up 202.41% YoY), while the FY2025 annual figure was $5.8 million, up 202.41% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $5.8 million, down from $6.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $6.4 million in Q2 2021, with the low at $640000.0 in Q3 2024.
- The 5-year median for Non-Current Deffered Revenue is $1.9 million (2025), against an average of $3.2 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue tumbled 87.64% in 2022, then soared 848.12% in 2025.
- Dianthus Therapeutics' Non-Current Deffered Revenue stood at $6.4 million in 2021, then sank by 87.64% to $791000.0 in 2022, then fell by 6.95% to $736000.0 in 2023, then soared by 159.24% to $1.9 million in 2024, then jumped by 202.41% to $5.8 million in 2025.
- Business Quant data shows DNTH's Non-Current Deffered Revenue at $5.8 million in Q4 2025, $6.1 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | 5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 6.07 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 640,000.00 |
| Jun 30, 2024 | 682,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 736,000.00 |
| Sep 30, 2023 | 745,000.00 |
| Dec 31, 2022 | 791,000.00 |
| Dec 31, 2021 | 6.40 Mn |
| Sep 30, 2021 | 6.40 Mn |
| Jun 30, 2021 | 6.40 Mn |
| Mar 31, 2021 | 6.36 Mn |
| Dec 31, 2020 | 6.30 Mn |
| Sep 30, 2020 | 6.21 Mn |
| Jun 30, 2020 | 6.44 Mn |
| Mar 31, 2020 | 6.34 Mn |
| Dec 31, 2019 | 6.21 Mn |